Validation of Novel Electrochemistry in a Combined Molecular & Immunoassay Point-of-Care Platform using Patient Samples: Application to Sexually Transmitted Diseases. As presented at ASM, May 2010. (Green, M. et al., 2010.)

  • Friday, 28 May 2010
  • in News

With the dramatic increase in the incidence of Chlamydia and the rising number of cases of Syphilis and Gonorrhoea there is an unmet need for a Point-of-Care (PoC) platform capable of providing multiplexed test results based on both rapid molecular and immunoassay methods. To address this need Atlas Genetics have developed a PoC platform, the Velox™ system, based on highly sensitive electrochemical detection technology. We have developed molecular assays for Chlamydia and Gonorrhoea, and an immunoassay for Syphilis based on this platform, with the results for each in less than 30 minutes.

Read 560 times